ArticleKidney international reports2022
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02808429 (A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy), which is not on this map. Cited by 55 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Who cites it
55 citing papers in PubMed, 6 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis.BMC nephrology · 2026Pooled it
- Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2025Pooled it
- Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Long-term renal survival in patients with IgA nephropathy: a systematic review.Renal failure · 2024Pooled it
- Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.Journal of nephrology · 2024Pooled it
- Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis.Frontiers in immunology · 2023Pooled it
- APRIL: spring forward also for IgA vasculitis nephritis in children.Pediatric nephrology (Berlin, Germany) · 2026Article
- Atacicept: First Approval.Drugs · 2026Article
- IgA nephropathy new therapies: from data in adults to application in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- APRIL-targeted and dual BAFF/APRIL blockade in primary IgA nephropathy: a systematic review and meta-analysis of randomized placebo-controlled trials.International urology and nephrology · 2026Review
- Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy.Frontiers in immunology · 2026Article
- Aberrant signaling in tonsillar B cells producing pathogenicFrontiers in immunology · 2026Review
- Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.Renal failure · 2025Article
- Transcriptomic Patterns in Adult and Pediatric Patients with IgA Nephropathy or IgA Vasculitis with Nephropathy.Journal of the American Society of Nephrology : JASN · 2025Article
- B Cell Activating Factor Does Not Play a Pivotal Role in the Synthesis of Aberrantly Glycosylated IgA.Nephrology (Carlton, Vic.) · 2025Article
- IgA Nephropathy: An Overview of the Clinical Trials.Kidney medicine · 2025Review
- Review
- Bridging pediatric and adult IgAN: challenges in applying proteinuria-driven recommendations in the new IPNA guidelines.Pediatric nephrology (Berlin, Germany) · 2025Article
- An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy.Advances in therapy · 2025Article
- Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes.Clinical kidney journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with IgA nephropathy (IgAN) and persistent proteinuria are at risk of progression to kidney failure. Atacicept is a novel B-cell-targeted immunomodulator, shown to reduce immunoglobulin levels in patients with autoimmune diseases. Methods: JANUS (NCT02808429) was a phase II study that assessed the safety, pharmacodynamic effects, and efficacy of atacicept in patients with IgAN and proteinuria ≥1 g/d or 0.75 mg/mg on 24-hour UPCR despite maximal standard of care therapy. Results: A total of 16 patients were randomized 1:1:1 to placebo ( Conclusion: Atacicept has an acceptable safety profile in patients with IgAN and is effective at reducing the levels of pathogenic factor Gd-IgA1, with potential improvements in proteinuria and renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.